Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-07-06Clinical Trial Update: Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers [Phase 3]
A Phase 3 safety study evaluating the co-administration of Menactra meningococcal vaccine with other pediatric vaccines in healthy toddlers;…
-
CLINICAL_TRIALS trial_result · 2011-06-15Clinical Trial Update: Correlation Between Cytokines and the Severity of Meningococcal Disease
This completed trial evaluated whether cytokine levels correlate with the severity of meningococcal disease (meningococcemia).
-
CLINICAL_TRIALS trial_result · 2011-03-04Clinical Trial Update: Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia [Phase 3]
Phase 3 trial in Saudi Arabia evaluated immunogenicity and safety of the Menactra meningococcal vaccine in adolescents; results were posted …
-
CLINICAL_TRIALS trial_result · 2011-01-14Clinical Trial Update: Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC [Phase 3]
This Phase 3 long-term persistence study evaluated a booster dose of GSK's Hib-MenC conjugate vaccine. The trial results were completed and …
-
FDA approval · 2010-11-10FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Rifadin IV (rifampin) by Sanofi-Aventis U.S. LLC to support its intravenous formulation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-10-04Clinical Trial Update: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents [Phase 3]
Phase 3 study evaluating the safety and immune response of the Novartis Meningococcal ACWY Conjugate Vaccine in adolescents has completed wi…
-
FDA approval · 2008-05-22FDA Approved: RIFAMPIN — Original Application (Mylan Institutional LLC)
FDA approved an Original Application for rifampin from Mylan Institutional LLC, enabling a generic rifampin product. This action approves th…
-
FDA approval · 2008-03-28FDA Approved: RIFAMPIN — Original Application (Chartwell RX, LLC)
FDA approved an Original Application (ANDA) for rifampin submitted by Chartwell RX, LLC. This marks approval of a generic rifampin product.
-
CLINICAL_TRIALS trial_result · 2007-12-27Clinical Trial Update: Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time [Phase 4]
Phase 4 study assessing the safety and immunogenicity of administering Prevnar (Prevenar) and Meningitec together in healthy participants; t…
-
CLINICAL_TRIALS trial_result · 2007-03-13Clinical Trial Update: Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age [Phase 3]
Phase 3 trial evaluating the immunogenicity, safety and tolerability of the Chiron Meningococcal C Conjugate Vaccine in healthy premature an…
-
CLINICAL_TRIALS trial_result · 2006-12-08Clinical Trial Update: Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants [Phase 2]
Phase 2 trial assessing immune response in infants after primary vaccination with Tritanrix-HepB mixed with three Hib-MenAC vaccine formulat…
-
CLINICAL_TRIALS trial_result · 2006-10-26Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age [Phase 4]
Phase 4 trial update reporting safety, tolerability, and immunogenicity data for the Meningococcal C Conjugate Vaccine in children aged 32 t…